Special Issue "CAR T Cells: A Road Trip to Tumor Elimination"
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 5451
CAR-T cell treatment has modified the concept of treatment for hematological malignancies in the last decade. Compared to traditional chemotherapy treatments, CAR-T cell treatment avoids the toxicities associated with continuous chemotherapy treatments, thereby improving patients' quality of life. Clinical results in pediatric patients with acute lymphoblastic leukemia have demonstrated maintained responses over the years due to the persistence of the CAR-T cells. However, in elderly cancer patients with hematological malignancies, CAR-T cells’ persistence is of shorter duration due, among other factors, to an aged immune system with immunosenescent T cells. Moreover, in solid tumors, CAR-T cells face barriers, such as those promoted by the tumor microenvironment, which decreases their efficacy. In addition, the presence of a heterogeneous mixture of cells in solid tumors and the lack of highly specific targets in this context decrease CAR-T cells' efficacy and lead to enhanced toxicities. In this regard, novel CAR constructs are being designed to avoid these problems. For instance, CAR-T cell activity can be modulated to prevent toxicities, and the CAR construct can be equipped with molecules that are secreted to fight the tumor microenvironment. Moreover, allogeneic universal CAR-T cells are being designed to decrease the costs associated with this therapy and obtain healthier CAR-T cells than those from cancer patients. Eventually, all these improvements are expected to improve the efficacy and safety of CAR-T cells in solid tumors and elderly cancer patients to achieve outstanding responses such as those obtained in pediatric acute lymphoblastic leukemia patients. This Special Issue offers an Open Access forum that aims to bring together a collection of original research and review articles addressing the main problems associated with this therapy and strategies to solve them in elderly patients with hematological malignancies and solid tumors.
We hope to provide stimulating literature for this growing field of immunotherapy. Suggested potential topics may include T cell immunosenescence; tumor microenvironment; modulation of CAR-T cell activity; CAR-T cell specificity; CAR-T cell efficacy; universal CAR-T cells, novel CAR constructs; neurotoxicity; cytokine release syndrome; on-target off-tumor toxicity.
Dr. Beatriz Martín-Antonio
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- CAR T cells
- cancer treatment
- tumor elimination
- chimeric antigen receptor
- cellular therapy
- tumor targeting
- tumor immunology
- CAR-T cell therapy